ArticleBMC ophthalmology2025
Safety and efficacy of stromal lenticule addition keratoplasty in the treatment of hyperopia: a retrospective study.
Article in BMC ophthalmology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
purposeThis study aimed to assess the safety and efficacy of stromal lenticule addition keratoplasty (SLAK) treatment in patients with hyperopia.
methodsThis retrospective study included 43 eyes from 34 patients treated with SLAK in the Corneal Refraction Department of Jinan Mingshui Eye Hospital from October 2022 to January 2024. The cohort included 14 males (17 eyes) and 20 females (26 eyes), with a mean age of 24.33 ± 9.03 years. Statistical analysis was performed on patient data collected before surgery and at 1 week, 1 month, 3 months, and 6 months post-surgery to compare the changes across different time periods. Changes in visual acuity, SE, KM, corneal thickness, and corneal biomechanics were evaluated. A visual corneal biomechanical analyzer (Corvis ST) was used to measure the time (A1T, A2T), length (A1L, A2L) and flattening speed (A1V, A2V) of the second corneal flattening level. Additional parameters such as maximum compression time (HCT), corneal curvature radius (HCR), peak distance (PD), maximum compression depth (DA), corneal first pressure hardness parameter (SP-A1), composite radius index (IR), and biomechanical correction intraocular pressure (bIOP) were also assessed.
resultsSignificant differences were observed in near vision (P < 0.001), uncorrected visual acuity (UCVA) (P < 0.001), and SE (P < 0.001) compared to pre-surgical data. There were also significant improvements in UCVA across different post-SLAK treatment periods (P < 0.05). Significant differences were observed in best-corrected visual acuity (BCVA) (0.43 ± 0.35) compared to UCVA (post-surgery) (F = 10.372, P < 0.001). Additionally, there were significant differences in Km, thinnest point of the cornea, and thickness of the central corneal epithelium compared to pre-surgical data (P all < 0.001). There were also significant differences in A1T, A2T, A2L, HCT, DA, and bIOP compared to pre-surgical data (P all < 0.05). There were no statistically significant differences in A1L, HCR, PD, SPA1, or IR (P all > 0.05).
conclusionsAt 6-month post-SLAK follow-up, hyperopic patients achieved expected visual and refractive outcomes. The procedure increased corneal curvature and thickness, prolonged corneal deformation time, and shortened deformation distance, suggesting enhanced corneal stiffness, with most biomechanical parameters remaining stable pre- to postoperatively.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.